BACKGROUND/AIM: To determine if early passage tumor cells obtained from patients with mesothelioma continue to express the tumor differentiation antigen mesothelin and their sensitivity to the anti-mesothelin immunotoxin SS1P. MATERIALS AND METHODS: Cell cultures were established from ascites or pleural effusion of 6 peritoneal and 3 pleural mesothelioma patients, respectively. These cells were evaluated for mesothelin expression by immunohistochemistry and flow cytometry. RESULTS: Although mesothelin was highly expressed in tumor biopsies of all patients, only 3 out of 9 malignant effusions from these patients when grown in short-term culture showed strong mesothelin positivity by IHC. By flow cytometry, the number of mesothelin sites per cell was variable ranging from 580 to 210,000 sites/cell. Cells with strong mesothelin expression by IHC and increased number of mesothelin sites/cell were sensitive to SS1P. CONCLUSIONS: Most mesothelioma tumors loose mesothelin when grown in vitro and the sensitivity of these cells to SS1P is dependent on the number of mesothelin sites/cell.
BACKGROUND/AIM: To determine if early passage tumor cells obtained from patients with mesothelioma continue to express the tumor differentiation antigen mesothelin and their sensitivity to the anti-mesothelin immunotoxin SS1P. MATERIALS AND METHODS: Cell cultures were established from ascites or pleural effusion of 6 peritoneal and 3 pleural mesotheliomapatients, respectively. These cells were evaluated for mesothelin expression by immunohistochemistry and flow cytometry. RESULTS: Although mesothelin was highly expressed in tumor biopsies of all patients, only 3 out of 9 malignant effusions from these patients when grown in short-term culture showed strong mesothelin positivity by IHC. By flow cytometry, the number of mesothelin sites per cell was variable ranging from 580 to 210,000 sites/cell. Cells with strong mesothelin expression by IHC and increased number of mesothelin sites/cell were sensitive to SS1P. CONCLUSIONS: Most mesothelioma tumors loose mesothelin when grown in vitro and the sensitivity of these cells to SS1P is dependent on the number of mesothelin sites/cell.
Authors: P Argani; C Iacobuzio-Donahue; B Ryu; C Rosty; M Goggins; R E Wilentz; S R Murugesan; S D Leach; E Jaffee; C J Yeo; J L Cameron; S E Kern; R H Hruban Journal: Clin Cancer Res Date: 2001-12 Impact factor: 12.531
Authors: H Shinohara; D Fan; S Ozawa; S Yano; M Van Arsdell; J L Viner; R Beers; I Pastan; I J Fidler Journal: Int J Oncol Date: 2000-10 Impact factor: 5.650
Authors: Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544
Authors: Andrew L Feldman; Steven K Libutti; James F Pingpank; David L Bartlett; Tatiana H Beresnev; Sharon M Mavroukakis; Seth M Steinberg; David J Liewehr; David E Kleiner; H Richard Alexander Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom Journal: Lancet Date: 2003-11-15 Impact factor: 79.321
Authors: Neetu Kalra; Jingli Zhang; Anish Thomas; Liqiang Xi; Mitchell Cheung; Jacqueline Talarchek; Sandra Burkett; Maria G Tsokos; Yuanbin Chen; Mark Raffeld; Markku Miettinen; Ira Pastan; Joseph R Testa; Raffit Hassan Journal: BMC Cancer Date: 2015-05-08 Impact factor: 4.430
Authors: Martin C Boonstra; Susanna W L de Geus; Hendrica A J M Prevoo; Lukas J A C Hawinkels; Cornelis J H van de Velde; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier Journal: Biomark Cancer Date: 2016-09-27